Elisabeth Leiderman
Director/Board Member chez BLUEBIRD BIO, INC.
Fortune : 28 488 $ au 31/03/2024
Profil
Elisabeth Leiderman is an Independent Director at bluebird bio, Inc. and a Non-Executive Director at Autolus Therapeutics Plc.
She previously worked as an Executive Director at Nomura Securities, Inc., VP-Business & Corporate Development at Fortress Biotech, Inc., Chief Business Officer at Complexa, Inc., Chief Financial & Accounting Officer at Decibel Therapeutics, Inc., and Chief Financial & Business Officer at Atsena Therapeutics, Inc. Dr. Leiderman holds an undergraduate degree from the University of Pennsylvania, an MBA from The Wharton School of the University of Pennsylvania, and a doctorate from Sackler School of Medicine.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
BLUEBIRD BIO, INC.
0,01% | 16/06/2023 | 22 256 ( 0,01% ) | 28 488 $ | 31/03/2024 |
Postes actifs de Elisabeth Leiderman
| Sociétés | Poste | Début |
|---|---|---|
| BLUEBIRD BIO, INC. | Director/Board Member | 15/10/2021 |
| AUTOLUS THERAPEUTICS PLC | Director/Board Member | 20/12/2023 |
Anciens postes connus de Elisabeth Leiderman
| Sociétés | Poste | Fin |
|---|---|---|
Atsena Therapeutics, Inc.
 Atsena Therapeutics, Inc. BiotechnologyHealth Technology Atsena Therapeutics, Inc. engages in biotechnology business. The company is headquartered in Durham, NC. | Director of Finance/CFO | 01/11/2023 |
| DECIBEL THERAPEUTICS, INC. | Director of Finance/CFO | 07/10/2022 |
Complexa, Inc.
 Complexa, Inc. Pharmaceuticals: MajorHealth Technology Complexa, Inc. operates as a biopharmaceutical company which engages on discovering and developing therapies for the treatment of severe and life-threatening fibrosis and inflammatory diseases. The firm focuses on two therapeutic areas: focal segmental glomerulosclerosis (FSGS) and pulmonary arterial hypertension (PAH), two rare diseases that can compromise the normal function of the kidney and the heart. The company was founded by Bruce A. Freeman, Raymond A. Miller, and Margaret M. Tarpey in 2008 and is headquartered in Berwyn, PA. | Corporate Officer/Principal | 01/08/2020 |
| Nomura Securities, Inc. | Director/Board Member | 01/07/2016 |
| FORTRESS BIOTECH, INC. | Corporate Officer/Principal | 01/01/2016 |
Formation de Elisabeth Leiderman
| University of Pennsylvania | Undergraduate Degree |
| The Wharton School of the University of Pennsylvania | Masters Business Admin |
| Sackler School of Medicine | Doctorate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 4 |
|---|---|
| FORTRESS BIOTECH, INC. | Health Technology |
| BLUEBIRD BIO, INC. | Health Technology |
| DECIBEL THERAPEUTICS, INC. | Health Technology |
| AUTOLUS THERAPEUTICS PLC | Health Technology |
| Entreprise privées | 3 |
|---|---|
Complexa, Inc.
Complexa, Inc. Pharmaceuticals: MajorHealth Technology Complexa, Inc. operates as a biopharmaceutical company which engages on discovering and developing therapies for the treatment of severe and life-threatening fibrosis and inflammatory diseases. The firm focuses on two therapeutic areas: focal segmental glomerulosclerosis (FSGS) and pulmonary arterial hypertension (PAH), two rare diseases that can compromise the normal function of the kidney and the heart. The company was founded by Bruce A. Freeman, Raymond A. Miller, and Margaret M. Tarpey in 2008 and is headquartered in Berwyn, PA. | Health Technology |
Atsena Therapeutics, Inc.
Atsena Therapeutics, Inc. BiotechnologyHealth Technology Atsena Therapeutics, Inc. engages in biotechnology business. The company is headquartered in Durham, NC. | Health Technology |
| Nomura Securities, Inc. |
